CCM
ZNTL icon

Copernicus Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Copernicus Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$532K – 18
2021
Q2 		$532K Buy
+10,000
New +$536K 8.39% 4

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Copernicus Capital Management's ZNTL Position: Q3 2021 in Review

Copernicus Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2021, closing a stake of 10,000 shares — an estimated $532K sold.

Copernicus Capital Management first reported a position in ZNTL in Q2 2021 and held it in 1 quarter. The position peaked at $532K in Q2 2021. 116 funds tracked by Wall St. Rank hold ZNTL as of Q3 2021.

  • Copernicus Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Copernicus Capital Management sold 10,000 Zentalis Pharmaceuticals shares in Q3 2021, an estimated $532K.
  • Copernicus Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Copernicus Capital Management's Zentalis Pharmaceuticals position peaked at $532K in Q2 2021.
  • 116 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2021.

Based on Copernicus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.